From start-up concept development to commercial launch

The prevalence of Peripheral Vascular disease is increasing worldwide,  fuelled by an aging population, growing rates of obesity, diabetes and end-stage-renal-disease. Coinciding with the increasing incidence of this disease is flourishing innovation in endovascular treatments. Our customer is advancing Minimally Invasive treatment of Peripheral Vascular disease in the lower extremities using the principles of biomimicry. Their highly innovative stents more closely mimic the natural geometry of the vasculature of the legs and offer improved resistance to the extreme compression, extension and flexion forces experienced in these arteries. An off-shoot from one of the world's leading medical institutions, the company was initially established to develop its novel stent design. Soon realizing the twin need for a suitable stent delivery solution the company turned to the TE design team.

A proven, ready-to-use stent delivery platform available from TE was leveraged by the customer, compressing the timeline to clinical evaluation of the novel self-expanding stent. The delivery platform features an outer sheath with a simple to use "pin and pull" system optimized for its ability to withstand the high deployment forces common with nitinol stent frames. The inner delivery system comprises core hypotube technology that ensures excellent stent deployment accuracy. Together, TE and the customer worked from start-up concept development to commercial launch. TE manages product manufacturing on behalf of the customer today, with a fully validated, packed, labelled and sterilised device shipped from our facilities to the customer's worldwide distribution network.